Treatment of disseminated granuloma annulare with fumaric acid esters

Alexander Kreuter
Thilo Gambichler
Peter Altmeyer
Norbert H. Brockmeyer

Department of Dermatology
Ruhr-University Bochum
Gudrunstrasse 56
44791 Bochum, Germany
Tel: +49-234-509-3473
Fax: +49-234-509-3475

Corresponding author:
(E-mail: t.gambichler@derma.de)
Abstract

Background
Granuloma annulare is a granulomatous disease of unknown etiology. Various therapies have been tried in disseminated forms of granuloma annulare (DGA), including corticosteroids, several variants of PUVA, UVA1, systemic retinoids, and dapsone, with variable success. We report a patient with recalcitrant DGA who was treated with fumaric acid esters (FAE).

Case presentation
A 40-year old Caucasian woman presented with a 25-year history of recalcitrant DGA. On both legs and the abdomen there were erythematous annular plaques. She was treated with FAE in tablet form using two formulations differing in strength (low strength tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt). After three-month therapy, an almost complete clearance of skin lesions was achieved. There were no adverse effects. The patient remained in remission during a six-month follow up period.

Conclusions
Our observation provides evidence that FAE is a potentially beneficial therapeutic option for patients with recalcitrant DGA. However, controlled trials are necessary to fully explore the efficacy, optimal dosage, and safety of FAE in the management of DGA.
**Background**

Granuloma annulare is a granulomatous disease of unknown etiology. Disseminated forms of granuloma annulare (DGA) are characterized by a chronic course of disease and frequent association with systemic disorders such as diabetes mellitus. Although spontaneous resolution can occur in some cases, particularly in localized granuloma annulare, various therapies have been tried in DGA, including corticosteroids, several variants of PUVA, UVA1, systemic retinoids, and dapsone, with variable success [1-5]. We report a patient with recalcitrant DGA who was treated with fumaric acid esters (FAE).

**Case presentation**

A 40-year old Caucasian woman presented with a 25-year history of DGA on both legs. Since one year, she also had lesions on the abdomen. Previous treatments with various therapeutic modalities (eg, corticosteroids, dapsone, and bath PUVA) were ineffective. On examination, she had erythematous annular plaques on the abdomen and on both legs (Fig. 1). Histopathologic examination of a punch biopsy specimen from the left leg revealed a normal epidermis. Below the epidermis there was mild collagen degeneration surrounded by palisading inflammatory cells. The infiltrates consisted of a mixture of monocytes, histiocytes, and occasional giant cells. These findings were consistent with the diagnosis of DGA. Complete work-up did not reveal evidence of malignancies, infections, and internal diseases such as diabetes mellitus.

Since the disease had been recalcitrant to various conventional therapies, we decided to start oral treatment with fumaric acid esters. The patient was treated with FAE
in tablet form using two formulations differing in strength (low strength tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt), supplied as Fumaderm® initial and Fumaderm® (Fumedica GmbH, Herne, Germany) [6]. Dosage of FAE was performed according to the standard therapy regimen for psoriasis patients displayed in Table 1. After two months, a complete clearance of skin lesions on the abdomen was achieved. Long-standing lesions on the legs improved after three-month therapy (Fig. 2). No side effects were observed during treatment. The patient remained in remission during a six-month follow up period.

**Discussion**

Fumaric acid has been shown to be an effective therapy option in patients with severe psoriasis vulgaris [6,7]. During therapy with fumaric acid a persistent decrease in the lymphocyte count and stimulation of TH2 cytokine responses have been observed. Since psoriasis is regarded as a TH1-type inflammatory disorder, the immunomodulation away from the TH1 cytokine IFN-γ to the TH2 cytokine IL-10 may lead to improvement of the disease. Furthermore, the anipsoriatic activity of fumaric acid may be mediated by diminishing proinflammatory cytokine overexpression and the antigen-presenting capacity of monocytes and macrophages [8,9].

It has been reported that FAE induce apoptosis in human dendritic cells as well as keratinocytes [10]. Histopathologically, localized granuloma as well as DGA are characterized by lymphohistiocytic and monocytic infiltrates that form palisading
granulomas with central necrobiotic changes. In a recent study, numerous apoptotic macrophages have been observed within the necrobiotic areas [11]. A popular view concerning pathogenesis holds that granuloma annulare is based on a delayed-type hypersensitivity reaction to as yet undefined cutaneous antigens. Phototherapy (eg, PUVA, UVA1) is effective in DGA and is known to suppress delayed hypersensitivity responses in the skin [3-5]. Previous findings suggest that a T cell-mediated immune response producing cytokines may be the dominant pathogenic factor in granuloma annulare [12]. Thus the efficacy of FAE in DGA may be mediate by similar immunomodulatory mechanisms that are observed in the treatment of psoriasis. Notably, it has been observed that treatment with FAE was also effective in cutaneous sarcoidosis which is closely related to granuloma annulare (P. Altmeyer, MD; unpublished data). Recently, Schulze-Dirks and Petzoldt [13] reported a female with a one-year history of DGA which resolved after six-week treatment of FAE. Since our patient had long-standing DGA, which was recalcitrant to potentially helpful therapeutic modalities, we do not consider that the therapeutic effect was due to spontaneous resolution.

FAE is a potentially beneficial therapeutic option for patients with recalcitrant DGA. Controlled trials are however necessary to fully explore the efficacy, optimal dosage, and safety of FAE in the treatment of DGA.

**List of abbreviations**

DGA: disseminated forms of granuloma annulare

FAE: fumaric acid esters
Competing interests
None declared

References
1 Dabski K, Winkelmann RK. Generalized granuloma annulare: Histopathology and immunology. Systematic review of 100 cases and comparison with localized granuloma annulare. J Am Acad Dermatol. 1989; 20:39-47.
2 Smith D, Downie JB, DiCostanzo D. Granuloma annulare. Int J Dermatol. 1997; 36:326-333.
3 Muchenberger S, Schöpf E, Simon JC. Phototherapy with UV-A-1 for generalized granuloma annulare. Arch Dermatol. 1997; 133:1605.
4 Salomon N, Walchner M, Messer G, Plewig G, Röcken M. Bath-PUVA therapy of granuloma annulare. Hautarzt 1999; 50:275-279.
5 Gambichler T, Menzel S. Cream PUVA in granuloma annulare. Z Dermatol. 1999; 185:124-127.
6 Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use. Br J Dermatol. 1999; 141:1605-1607.
7 Altmeyer P, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, et al. Antipsoriatic effect of fumaric acid derivate. J Am Acad Dermatol. 1994; 30:977-981.
8 De Jong R, Bezemer AC, Zomerdijk PL, van de Puv-Kraan, Ottenhoff HM, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996; 26:2067-2074.
9 Asadullah K, Schmid H, Friedrich M, Randow F, Volk H, Sterry W, et al. Influence of monomethylfumarate on monocytic cytokine formation – explanation for adverse and therapeutic effects in psoriasis. Arch Dermatol Res. 1997; 289:623-630.
10 Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001; 116:203-208.
11 Fayyazi A, Schweyer S, Eichmeyer B, Herms J, Hemmerlein B, Radzun HJ, Berger H. Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch Dermatol Res 2000; 292:384-390.
12 Buechner SA, Winkelmann RK, Banks PM. Identification of T-cell subpopulations in granuloma annulare. Arch Dermatol. 1983; 119:125-128.
13 Schulze-Dirks A, Petzoldt D. Disseminated granuloma annulare – successful therapy with fumaric
Table 1. Dosage schedule of FAE for the treatment of the presented patient with DGA

| Week | Morning* | Noon* | Evening* | FAE formulation       |
|------|----------|-------|----------|-----------------------|
| 1    | 1        | -     | -        | Fumaderm® initial     |
| 2    | 1        | -     | 1        | Fumaderm® initial     |
| 3    | 1        | 1     | 1        | Fumaderm® initial     |
| 4    | 1        | -     | -        | Fumaderm®             |
| 5    | 1        | -     | 1        | Fumaderm®             |
| 6-12 | 1        | 1     | 1        | Fumaderm®             |

*= number of tablets

Figure 1. Long-standing granuloma annulare on the left leg.
Figure 2. Almost complete clearance of granuloma annulare after 3 months of therapy with FAE.
